About Us

Indication Bioscience is a forward-thinking biopharmaceutical company dedicated to addressing critical unmet needs in cardiovascular care. Our lead program, Atorvo+, is a novel fixed-dose combination therapy designed to improve statin tolerance and adherence by mitigating the muscle-related side effects often associated with statin use. Our Phase I pharmacokinetics (PK) study, approved by the Alfred Health Human Research Ethics Committee (HREC) and managed by Novotech at Nucleus Network, marks a significant milestone in our mission to enhance patient outcomes. Backed by a robust intellectual property portfolio and a leadership team with proven expertise in drug development, including the launch of Lipitor and Phase III trials for bempedoic acid, Indication Bioscience is poised to redefine the standard of care for cholesterol management.

Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering pharmaceuticals, and are among the most widely prescribed class of drugs. The Statin+ concept represents a groundbreaking approach to cholesterol management by combining proven statin therapies with complementary active ingredients to address the widespread challenge of statin intolerance. By targeting the muscle-related side effects that lead to poor adherence, Statin+ therapies aim to enhance tolerability and improve patient outcomes. This innovative fixed-dose combination strategy leverages existing FDA-approved therapies through accelerated development pathways, offering a de-risked and cost-effective solution to optimize treatment adherence in millions of patients globally.